TY - JOUR
T1 - Massive Transfusion Protocols in Obstetric Hemorrhage
T2 - Theory versus Reality
AU - Salmanian, Bahram
AU - Clark, Steven L.
AU - Hui, Shiu Ki R.
AU - Detlefs, Sarah
AU - Aalipour, Soroush
AU - Meshinchi Asl, Nazlisadat
AU - Shamshirsaz, Alireza A.
N1 - Publisher Copyright:
© 2023 Thieme Medical Publishers, Inc.. All rights reserved.
PY - 2023/1
Y1 - 2023/1
N2 - Objective Massive transfusion protocols are widely implemented in obstetrical practice in case of severe hemorrhage; however, different recommendations exist regarding the appropriate ratios of blood product components to be transfused. We report our extensive experience with massive component transfusion in a referral center in which the standard massive transfusion protocol is modified by ongoing clinical and laboratory evaluation. Study Design A retrospective chart review of all patients who had massive transfusion protocol activation in a level 4 referral center for obstetrical practice was performed from January 2014 to January 2020. Data collected included the etiology of obstetrical hemorrhage, number of blood products of each type transfused, crystalloid infusion, and several indices of maternal morbidity and mortality. Data are presented with descriptive statistics. Results A total of 62 patients had massive transfusion protocol activation, of which 97% received blood products. Uterine atony was found to be the most common etiology for massive hemorrhage (34%), followed by placenta accreta spectrum (32%). The mean estimated blood loss was 1,945 mL. A mean of 6.5 units of packed red blood cells, 14.8 units of fresh frozen plasma and cryoprecipitate, and 8.3 units of platelets were transfused per patient. No maternal deaths were seen. Conclusion The ratios of transfused packed red blood cell to fresh frozen plasma/cryoprecipitate and of packed red blood cell to platelet units varied significantly from the fixed initial infusion ratio called for by our massive transfusion protocol resulting in universally favorable maternal outcomes. When rapid laboratory evaluation of hematologic and clotting parameters is available, careful use of this information may facilitate safe modification of an initial fixed transfusion ratio based on etiology of the hemorrhage and individual patient response. Key Points Massive transfusion protocols in obstetrics follow fixed ratios of blood products. Actual usage of blood components is different than the standardized protocols. We recommend to modify the initial fixed transfusion ratio according to clinical response.
AB - Objective Massive transfusion protocols are widely implemented in obstetrical practice in case of severe hemorrhage; however, different recommendations exist regarding the appropriate ratios of blood product components to be transfused. We report our extensive experience with massive component transfusion in a referral center in which the standard massive transfusion protocol is modified by ongoing clinical and laboratory evaluation. Study Design A retrospective chart review of all patients who had massive transfusion protocol activation in a level 4 referral center for obstetrical practice was performed from January 2014 to January 2020. Data collected included the etiology of obstetrical hemorrhage, number of blood products of each type transfused, crystalloid infusion, and several indices of maternal morbidity and mortality. Data are presented with descriptive statistics. Results A total of 62 patients had massive transfusion protocol activation, of which 97% received blood products. Uterine atony was found to be the most common etiology for massive hemorrhage (34%), followed by placenta accreta spectrum (32%). The mean estimated blood loss was 1,945 mL. A mean of 6.5 units of packed red blood cells, 14.8 units of fresh frozen plasma and cryoprecipitate, and 8.3 units of platelets were transfused per patient. No maternal deaths were seen. Conclusion The ratios of transfused packed red blood cell to fresh frozen plasma/cryoprecipitate and of packed red blood cell to platelet units varied significantly from the fixed initial infusion ratio called for by our massive transfusion protocol resulting in universally favorable maternal outcomes. When rapid laboratory evaluation of hematologic and clotting parameters is available, careful use of this information may facilitate safe modification of an initial fixed transfusion ratio based on etiology of the hemorrhage and individual patient response. Key Points Massive transfusion protocols in obstetrics follow fixed ratios of blood products. Actual usage of blood components is different than the standardized protocols. We recommend to modify the initial fixed transfusion ratio according to clinical response.
KW - massive transfusion
KW - obstetric hemorrhage
KW - postpartum hemorrhage
KW - Pregnancy
KW - Blood Component Transfusion/methods
KW - Humans
KW - Female
KW - Retrospective Studies
KW - Placenta Accreta
KW - Blood Transfusion/methods
KW - Hemorrhage
UR - http://www.scopus.com/inward/record.url?scp=85106179485&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106179485&partnerID=8YFLogxK
U2 - 10.1055/s-0041-1728833
DO - 10.1055/s-0041-1728833
M3 - Article
C2 - 33990124
AN - SCOPUS:85106179485
SN - 0735-1631
VL - 40
SP - 95
EP - 98
JO - American Journal of Perinatology
JF - American Journal of Perinatology
IS - 1
ER -